Sex based pharmacological treatment in patients with metabolic syndrome: Findings from the Isfahan healthy heart program

African Journal of Pharmacy and Pharmacology

Volumn 5, Issue 3, 2011, Pages 311-316

  Gharipour, Mojgan ^a   Kelishadi, Roya ^a   Toghianifar, Nafiseh ^a   Mackie, Mahsa ^b   Yazdani, Mehrdad ^a   Noori, Fatemeh ^a   Sarrafzadegan, Nizal ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Compliance; Iran; Metabolic syndrome; Pharmacological treatment

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NICOTINIC ACID; THIAZIDE DIURETIC AGENT; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEALTH PROGRAM; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IRAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATIENT ATTITUDE; PERSONALIZED MEDICINE; RISK ASSESSMENT; RISK FACTOR;

EID: 79957984345     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: 10.5897/AJPP10.205     Document Type: Article

References (22)

1. Alsaraj F, McDermott JH, Cawood T, McAteer S, Ali M, Tormey W, et al (2009). Prevalence of the metabolic syndrome in patients with diabetes mellitus. Ir. J. Med. Sci., Jun 4.
2. Bianchi C, Penno G, Romero F, Del PS, Miccoli R (2007). Treating the metabolic syndrome. Expert. Rev. Cardiovasc. Ther., 53: 491-506.
3. Bjornsson E (2008). The clinical aspects of non-alcoholic fatty liver disease. Minerva. Gastroenterol. Dietol., 54(1): 7-18.
4. Deedwania PC, Gupta R (2006). Management issues in the metabolic syndrome. J. Assoc. Phys. icians India., 54: 797-810.
5. Deedwania PC, Volkova N (2005). Current Treatment Options for the Metabolic Syndrome. Curr. Treat. Options Cardiovasc. Med., May; 7(1): 61-74.
6. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R (2009). First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care., 32(6): 1092-7.
7. Esteghamati A, Abbasi M, Nakhjavani M, Yousefizadeh A, Basa AP, Afshar H (2006). Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. Cardiovasc Diabetol., 5: 15.
8. Gasparyan AY, Watson T, Lip GY (2008). The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J. Am. Coll. Cardiol., 13; 51(19): 1829-43.
9. Grundy SM (2005). Metabolic syndrome: therapeutic considerations (2005). Handb. Exp. Pharmacol., 170: 107-33.
10. Grundy SM, Brewer HB, Jr, Cleeman JI, Smith SC, Lenfant C (2004).: Definition of metabolic syndrome (2004). Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation., 109: 433-8.
11. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 25; 112(17): 2735-52.
12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit. Pathw. Cardiol., 4(4): 198-203.
13. Israili ZH, Lyoussi B, Hernandez-Hernandez R, Velasco M (2007). Metabolic syndrome: treatment of hypertensive patients. Am. J. Ther., 14(4): 386-402.
14. Khosravi ArR, Shirani Sh, S, hahrokhish, Mohammadifard N, Ansari R (2006). Antihypertensive drugs used by hypertensive patients in the provincial cities of isfahan, najafabad and arak. ARYA. Atherosclerosis. J., 1(4): 275-280.
15. Misra A, Chaudhary D, Vikram NK, Mittal V, Devi JR, Pandey RM (2002). Insulin resistance and clustering of atherogenic risk factors in women belonging to low socio-economic strata in urban slums of North India. Diabetes Res Clin. Pract., 56(1): 73-5.
16. Pacholczyk M, Ferenc T, Kowalski J (2008). Metabolic syndrome. Part III: its prevention and therapeutic management. Postepy. Hig. Med. Dosw., 62: 559-70.
17. Sarrafzadegan N, Baghaei AM, Sadri GH, Kelishadi R, Malekafzali H, Boshtam M, et al (2006). Isfahan healthy heart program: Evaluation of comprehensive, community-based interventions for noncommunicable disease prevention. Prevention Control., 2: 73-84.
18. Sarrafzadegan N, Kelishadi R, Baghaei A, Hussein SG (2008),. Malekafzali H, Mohammadifard N (2008). Metabolic syndrome: an emerging public health problem in Iranian Women: Isfahan Healthy Heart Program. Int. J. Cardiol., 2008, 17; 131(1): 90-6.
19. Sarrafzadegan N, Kelishadi R, Dana Siadat Z, Esmaillzadeh A, Solhpour A, Shirani S, Naderi G, Asgary S, Sadri G, Khosravi A, Bahonar A (2009). Obesity and cardiometabolic risk factors in a representative population of Iranian adolescents and adults in comparison to a Western population: the Isfahan Healthy Heart Programme. Public. Health. Nutr., 6: 1-10.
20. Sarrafzadegan N, Kelishadi R, Esmaillzadeh A, Mohammadifard N, Rabiei K, Roohafza H, et al (2009). Do lifestyle interventions work in developing countries? Findings from the Isfahan Healthy Heart Program in the Islamic Republic of Iran. Bull. World. Health. Organ., 87(1): 39-50.
21. Sarraf-Zadegan N, Sadri G, Malek AH, Baghaei M, Mohammadi FN, Shahrokhi S, et al (2003). Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta. Cardiol., 58(4): 309-20.
22. Tavassoli AA, Gharipour M, Siadat ZD, Bahonar A, Sadary GH (2010). Are obesogenic behavioral, socioeconomic and metabolic determinants different in Iranian men and women? Health Popul. Nutr., 2010; 28(6): 602-609.